 Home > Active Ingredient News > Endocrine System > Eur Heart J: The effect of empagliflozin on patients with heart failure with different ejection fractions

Eur Heart J: The effect of empagliflozin on patients with heart failure with different ejection fractions

 Last Update: 2021-12-26
 Source: Internet
 Author: User

Tags

heart healthy protein

heart dissection labeled

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Currently, there is no therapy in clinical practice that can reduce the hospitalization risk of heart failure patients with different ejection fraction ranges
.

Recently, the heart blood vessels magazine field authority Eur Heart published a research article on J, the purpose of the study was to assess the ejection fraction of sodium - cotransporter 2 inhibitor Protein Eng column net outcome of heart failure glucose
.

Blood vessel

Researchers performed a pooled analysis of the EMPEROR-decreased and EMPEROR-normal trials (9718 patients; 4860 received empagliflozin and 4858 received placebo).
Patients were grouped according to ejection fraction: <25%(n =999), 25-34%(n=2230), 35-44%(n=1272), 45-54%(n=2260), 55-64%(n=2092) and ≥65%(n= 865)
.

Outcomes assessed include (i) the length of hospitalization for the first time due to heart failure or cardiovascular death, (ii) the length of time to the first hospitalization for heart failure, (iii) the total length of hospitalization (first and recurrence) due to heart failure, and ( iv) Assessed health status Kansas City Cardiomyopathy Questionnaire (KCCQ)

As the ejection fraction increased from <25% to ≥65%, the risk of cardiovascular death and hospitalization for heart failure gradually decreased
.

Enpagliflozin reduces the risk of cardiovascular death or heart failure hospitalization, mainly by reducing heart failure hospitalization

It can be seen that the degree of influence of empagliflozin on the outcome of heart failure has clinical significance in patients with ejection fraction <25% to <65%, and the effects of each group are similar, but in patients with ejection fraction ≥65% Has weakened
.

The effect of empagliflozin on the outcome of heart failure is clinically significant in patients with ejection fraction <25% to <65%, and the effects of each group are similar, but it is weakened in patients with ejection fraction ≥65%
.

Original source:

Javed Butler.

Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.